Literature DB >> 3882125

A sequential comparison of etretinate (Tigason) and isotretinoin (Roaccutane) with special regard to their effects on serum lipoproteins.

C Vahlquist, G Michaëlsson, A Vahlquist, B Vessby.   

Abstract

Etretinate and isotretinoin were compared with respect to their clinical effects and changes in serum lipoprotein concentrations. Sixteen patients with hyperkeratotic and pustular disorders of hands and feet (mainly palmoplantar pustulosis) underwent a double-blind cross-over study. The daily doses of etretinate and isotretinoin were 50 and 40 mg, respectively. Each drug was given for 2 months with a 2-month intermission. The clinical score was reduced both by isotretinoin (P less than 0.05) and etretinate (P less than 0.001). Both drugs affected the lipoprotein concentrations. Isotretinoin increased the cholesterol concentration in low-density lipoprotein (LDL) by 20% and the triglyceride concentration in very low-density lipoprotein (VLDL) by 35%, but decreased the high-density lipoprotein cholesterol by 12%. Etretinate elevated LDL-cholesterol by 10%. These changes had reverted to normal 8 weeks after the end of treatment. The data suggest that in the diseases studied, etretinate is preferable to isotretinoin with regard to both clinical effect and serum lipid side-effects.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3882125     DOI: 10.1111/j.1365-2133.1985.tb02293.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  5 in total

Review 1.  Adverse effects of retinoids.

Authors:  M David; E Hodak; N J Lowe
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Jul-Aug

Review 2.  Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases.

Authors:  F G Larsen; F Nielsen-Kudsk; P Jakobsen; K Weismann; K Kragballe
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

3.  Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.

Authors:  N Vu-Dac; P Gervois; I P Torra; J C Fruchart; V Kosykh; T Kooistra; H M Princen; J Dallongeville; B Staels
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

Review 4.  Adverse reactions to oral retinoids. An update.

Authors:  C M Mills; R Marks
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

Review 5.  Interventions for chronic palmoplantar pustulosis.

Authors:  A M Marsland; R J G Chalmers; S Hollis; J Leonardi-Bee; C E M Griffiths
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.